ArticleLancet regional health. Americas2025
Risk factors for Alzheimer's disease and cognitive function before middle age in a U.S. representative population-based study.
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- State Policy Liberalism in Adolescence and Risk for Dementia from 2000 to 2016 among Older U.S. Adults.Journal of health and social behavior · 2026Article
- Alzheimer neuropathological change, α-synuclein and transactive response DNA-binding protein of 43 kDa expression in children and young adult brains from forensic autopsies: Value for early measurement of abnormal protein expression prevalence in neurodegenerative diseases.Journal of neuropathology and experimental neurology · 2026Article
- Outcome-specific risk factors challenge universal dementia prevention priorities: Findings from the Egyptian Dementia Network Registry.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The physiological effects of APOE genotype in healthy young/middle-aged individuals.Biological reviews of the Cambridge Philosophical Society · 2026Article
- APOE and plasma AD biomarkers: The role of genetic ancestry in Hispanics/Latinos.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Relationships between heritable dementia risk factors, cardiovascular risk factors in young adulthood, and midlife neuropsychological outcomes.Journal of Alzheimer's disease : JAD · 2026Article
- Reductions in brainstem volume as a key macrostructural indicator in at-risk populations for Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Air pollution is a major risk factor for the development of Alzheimer's disease, cognition deficits, systemic and neural inflammation in urban children.Lancet regional health. Americas · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Alzheimer's disease is a major health concern in the U.S., but most research has focused on older populations. We examined whether established risk factors and blood biomarkers are associated with cognition before midlife. Methods: Data from the National Longitudinal Study of Adolescent to Adult Health (Add Health) were analyzed. Participants were enrolled in 1994-95 (grades 7-12) and followed through 2018. We cross-sectionally analyzed weighted survey and biomarker data from Waves IV and V. We measured the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) score comprised of age, education, sex, systolic blood pressure, body mass index, cholesteroal, and physical activity and apolipoprotein E ε4 allele (APOE ε4) status. We also measured total Tau and Neurofilament light (NfL), high sensitivity C-reactive protein (hsCRP), Interleukin (IL)-1β, IL-6, IL-8, IL-10, and Tumor necrosis factor alpha (TNF-α). Outcomes included immediate word recall, delayed word recall, and backward digit span. Findings: Analytic sample sizes ranged from 4507 to 11,449 participants in Wave IV and from 529 to 1121 participants in Wave V. The survey-weighted median (IQR) age was 28 (26-29) years in Wave IV and 38 (36-29) years in Wave V. About half of the survey-weighted Wave IV participants were female (48.4-52.1% across analytic samples), 71.4-72.5% were White, 12.5-14.9% were Black, and 9.3-10.2% were Hispanic. In Wave V, 43.6-46.8% were female, 68.7-69.3% were White, 17.1%-20.0% were Black, and 7.3%-9.6% were Hispanic. The CAIDE score was associated with all cognition measures in Wave IV. For example, among adults aged 24-34, each 1-point increase in CAIDE was associated with a 0.03 standard deviation lower backward digit span score (95% CI: -0.04, -0.02). Total Tau was associated with immediate word recall in Wave V (β = -0.13, 95% CI: -0.23, -0.04). Wave IV hsCRP and IL-10 and Wave V IL-6, IL-1β, and IL-8 were also associated with lower cognitive scores. Interpretation: Key risk factors for Alzheimer's Disease are linked to cognitive function as early as ages 24-44, highlighting the need for early prevention in the US. Funding: NIHP01HD31921, U01AG071448, U01AG071450, R01AG057800, P30AG066615, T32HD091058, P2CHD050924.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.